Press Releases

Grifols ranked number one biotech company in Dow Jones Sustainability Indices December 16 2024

Grifols concludes balance sheet improvement process with private placement of Senior Secured Notes and Revolving Credit Facility extension December 11 2024

Grifols’ Board of Directors Announces Termination of Acquisition Discussions with Brookfield November 27 2024

Grifols Delivers Strong Third-Quarter Performance Led by Biopharma 12.1% Growth November 7 2024

Grifols awarded Gold Medal by EcoVadis for Sustainability Excellence November 5 2024

Thomas Glanzmann becomes non-executive Chairman September 23 2024

Grifols Accelerates Performance in Q2 and Reaffirms Full Year Guidance July 30 2024

Grifols and Andorran government agree not to proceed with immunology research center July 25 2024

Grifols appoints Rahul Srinivasan as new Chief Financial Officer July 4 2024

Grifols’ Biotest to achieve USD 1 billion in US sales of Yimmugo® over next seven years July 1 2024

Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier Group June 18 2024

Grifols shareholders approve all agenda items at 2024 Annual General Meeting June 14 2024

Grifols succesfully closes the issuance of additional EUR 300 million secured notes June 4 2024

Grifols on track to meet full-year guidance and reduce debt May 14 2024

Grifols on track to close its strategic alliance with Haier in first half 2024 May 6 2024

Grifols successfully completes its EUR 1 billion private placement of senior secured notes April 30 2024

Grifols announces signing of private offering of EUR 1 billion senior secured notes due 2030 April 23 2024

Nacho Abia begins tenure as new Grifols CEO April 2 2024

Grifols shares CNMV statement March 25 2024

Grifols closes a record year and accelerates profitable growth for 2024 February 29 2024

Grifols announces changes in governance to separate management from ownership as part of planned strategy February 5 2024

Grifols’ Credit Rating Affirmed by S&P Global; Outlook Stable January 19 2024

Grifols reaches strategic alliance with Haier Group and raises approximately USD 1.8 billion December 29 2023

Victor Grifols Roura announces retirement from the Board of Directors; Albert Grifols Coma-Cros appointed as new Board Member December 19 2023

Grifols renews its inclusion in the Dow Jones Sustainability Indices as one of the world s most sustainable companies December 11 2023

Grifols accelerates EBITDA margin expansion to 25.1% and further improves its operating performance November 2 2023

Grifols delivers 15% revenue growth, accelerates margin expansion in Q2 and raises guidance for FY23 July 27 2023

Grifols delivers strong first quarter financials with 23% revenue growth and an Adjusted EBITDA margin above guidance of 21% May 9 2023

Grifols realigns management structure to accelerate company performance and simplify its corporate governance May 8 2023

Grifols delivers strong 2022 performance and is positioned for sustainable future growth February 28 2023

Thomas Glanzmann new Grifols Executive Chairman, after Steven F. Mayer resignation February 21 2023

Grifols announces comprehensive operational improvement plan including EUR 400 million annualized cost savings initiative February 15 2023

Grifols included in Bloomberg Gender-Equality Index for the third consecutive year for its leadership in equality, diversity and inclusion January 31 2023

Grifols recognized as one of the world’s most sustainable companies by Dow Jones Sustainability Index for third consecutive year December 12 2022

Grifols’ Biopharma delivers robust 34% operational growth in Q3, driving revenues to EUR 4,351m in the first nine months of 2022 November 8 2022

Grifols invites to listen to webcast of November 8 Conference Call with Analysts November 4 2022

Victor Grifols Roura decides to retire as Chairperson; Grifols appoints private equity veteran Steven F. Mayer as Executive Chairperson October 3 2022

Board of Directors communication in the context of considerable geopolitical uncertainty and market volatility September 26 2022

Grifols’ credit rating reaffirmed by Moody’s and Fitch based on strong fundamentals and improving performance September 23 2022

Grifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada September 7 2022

Grifols’ business momentum delivers EUR 2,810 million in revenues and EUR 618 million in EBITDA as plasma collections accelerate July 28 2022

Grifols highlights the acceleration of its operating performance and reiterates its strong commitment to debt reduction June 16 2022

Grifols highlights an increase in plasma and underscores innovation and sustainability as key growth pillars in its AGM June 10 2022

Business Update 1Q 2022: Grifols accelerating plasma recovery while enhancing performance May 6 2022

Grifols completes the acquisition of Biotest: a strategic and transformational transaction to accelerate growth and innovation April 25 2022

Grifols demonstrates resilient performance despite a challenging backdrop while recovery in plasma collection gains momentum February 28 2022

Grifols signs global collaboration agreement with Endpoint Health to develop and commercialize Antithrombin III for Sepsis February 24 2022

Grifols maintains its standing in the Bloomberg Gender-Equality Index for its commitment to equality January 26 2022

Grifols achieves a high level of acceptance of its PTO to Biotest and advances on its strategic transaction January 26 2022

Grifols announces the expiration of the Asset sale Offer January 11 2022

Grifols moves forward with its divestment plan by agreeing to sell VCN Biosciences December 14 2021

Grifols announces the commencement of an Asset sale Offer December 13 2021

Grifols and GIC obtain authorization for their strategic agreement for USD 1 billion November 17 2021

Grifols is included on the Dow Jones Sustainability World Index November 15 2021

Grifols advances on the execution of its strategic plan November 11 2021

Grifols earns approval for the voluntary public tender offer of Biotest and advances its strategy to increase the availability of plasma-derived medicines October 26 2021

Grifols increases access to plasma-derived therapies as part of its commitment to donors and patients October 13 2021

Grifols divests its hemostasis technology business for USD 25 million October 6 2021

Grifols closes its EUR 2 billion bond issuance to finance its investment in Biotest October 5 2021

Grifols earns its first Fitch corporate rating with a BB- and stable outlook September 27 2021

Grifols announces its investment in Biotest September 17 2021

Grifols advances on its strategic investment from GIC with 90% of consents from its notes holders and lenders August 16 2021

Grifols signs an agreement with ImmunoTek to open 21 plasma centers and further advances on its expansion plan July 30 2021

The Bioscience Division grows 5.1% in the second quarter and raises first-half revenues to EUR 2,537 million July 29 2021

Grifols endorses its commitment to a responsible business model and support of the 2030 Agenda for Sustainable Development by formally joining the United Nations Global Compact July 20 2021

Grifols announces a strategic investment from GIC of USD 1 billion June 30 2021

Grifols reaffirms its commitment to sustainability and innovation in its AGM and celebrates its 15th anniversary of being listed May 21 2021

Grifols maintains its revenues and operational levels while enhancing its innovation strategy and securing its plasma supply May 4 2021

Grifols advances in the execution of its expansion plan with the acquisition of 7 plasma centers in the U.S. April 7 2021

Grifols announces topline data from NIAID Phase 3 ITAC trial (INSIGHT-013) evaluating hyperimmune globulins as a treatment for hospitalized patients with COVID-19 April 2 2021

Grifols reinforces its innovation strategy after completing the acquisition of GigaGen to boost a novel method to generate a wide range of immunoglobulins March 9 2021

Grifols publishes its 2020 Integrated Annual Report as part of its commitment to sustainability March 4 2021

Grifols acquires 25 U.S.-based plasma centers from BPL ensuring one million additional liters for fractionation March 1 2021

Grifols increases its revenues to 5,340 M€ and continues to demonstrate its resilience and commitment to sustainable growth February 26 2021

Grifols is included in the Bloomberg Gender-Equality Index for its commitment to gender equality January 27 2021